Saham Gland Pharma sentuh rekor tertinggi 52 pekan usai rilis laporan keuangan

Rabu, 20 Mei 2026

Dilaporkan oleh AI

Saham Gland Pharma mencapai rekor tertinggi baru dalam 52 pekan setelah perusahaan melaporkan kinerja yang kuat untuk kuartal Maret dan setahun penuh. Unit Eropa, Cenexi, menunjukkan tanda-tanda pemulihan, sementara peluncuran produk baru dan penambahan kapasitas turut mendukung prospek perusahaan.

Saham Gland Pharma naik ke level tertingginya dalam setahun menyusul rilis angka kuartalan dan tahunan yang solid. Perusahaan menyoroti peningkatan profitabilitas di anak usahanya di Eropa, Cenexi, sebagai faktor positif utama.

Artikel Terkait

Laurus Labs stock rises 30 percent on FY26 results

Laurus Labs reported strong financial results for fiscal 2026, driving a 30 percent gain in its share price. Growth in contract manufacturing and a better product mix supported the performance.

Sun Pharma reports strong quarterly growth but eyes margin pressure

Minggu, 24 Mei 2026 Dilaporkan oleh AI

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Europe

Profits rise at DAX companies despite falling revenues

Business

Retail investors gain from small-cap stock rallies

Africa

JSE companies report strong earnings growth in latest updates

European equities suffer steep weekly losses amid Middle East tensions

European stocks closed the week lower on Friday, with the STOXX 600 index hitting a two-week low. Investors cited concerns over growth and inflation from the ongoing Middle East conflict disrupting energy supplies. While technology shares gained, healthcare and financial sectors declined.

Nine BSE smallcap stocks surged up to 170% with strong Q4 profits

Jumat, 01 Mei 2026 Dilaporkan oleh AI

Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.

Business